AI Article Synopsis
- * A study of 283 AD patients treated with upadacitinib (15 mg or 30 mg) revealed significant reductions in eczema severity and itchiness over 48 weeks, alongside decreased total eosinophil counts (TEC).
- * The changes in TEC correlated with improvements in eczema and itch scores, suggesting TEC may serve as a potential biomarker for monitoring treatment response; however, further research is needed to confirm its effectiveness for this purpose.
Article Abstract
Background: Atopic dermatitis (AD) is a chronic skin disease characterized by type 2-skewed immune responses, and significantly influenced by cytokines dependent on Janus kinases (JAKs). Upadacitinib, a JAK1 inhibitor, is effective for moderate-to-severe AD. This study aims to identify biomarkers that reflect long-term therapeutic effects of upadacitinib 15 mg or 30 mg.
Methods: A retrospective study from August 2021 to July 2023 included 213 AD patients treated with upadacitinib 15 mg and 70 AD patients with 30 mg. We analyzed eczema area and severity index (EASI), peak pruritus-numerical rating scale (PP-NRS), serum immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) at weeks 0, 4, 12, 24, 36, and 48 of treatment.
Results: Both treatments with upadacitinib 15 mg and 30 mg significantly reduced EASI and PP-NRS scores over week 4 to 48 compared to baseline. Upadacitinib 15 mg or 30 mg treatment significantly decreased TEC compared to baseline through week 4 to 36 or week 4 to 48, respectively. The percent reduction of TEC correlated with those of EASI and PP-NRS through week 4 to 48 of treatment with upadacitinib 15 mg, or through week 12 to 48 with 30 mg, respectively. After adjusting for % reductions of other laboratory markers, the significance of correlations was preserved at weeks 36 and 48 of 15 mg treatment, while at weeks 4 and 36 of 30 mg treatment.
Conclusion: The % reduction of TEC correlated with those of EASI and PP-NRS during upadacitinib treatment, indicating its potential as a biomarker reflecting treatment responses to upadacitinib in AD patients. However, the variability of significant correlation during treatment indicates that further inspection is needed for its usefulness in monitoring responses to upadacitinib treatment for AD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091278 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1365544 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan.
Eur J Dermatol
October 2024
Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Niazi, Japan.
Article Synopsis
- Tralokinumab, a human monoclonal antibody, is an approved treatment for atopic dermatitis (AD) and was evaluated for its effectiveness and safety in Japanese patients between October 2023 and March 2024.
- In a study involving 103 patients, significant improvements in eczema severity were observed at weeks 4 and 12, including notable reductions in the Eczema Area and Severity Index (EASI) scores and itch intensity.
- The treatment was generally well-tolerated, with mild and manageable side effects reported in 14.8% of patients, including a low incidence of conjunctivitis that resolved on its own.
Unveiling the Impact of Moderate and Severe Atopic Dermatitis: Insights on Burden, Clinical Characteristics, and Healthcare Resource Utilization in Adult Greek Patients from the APOLO Cross-Sectional Study.
J Clin Med
October 2024
Pfizer Hellas SA, 15451 Neo Psichiko, Greece.
Article Synopsis
- * A study in Greece involved 184 adults, revealing that many suffer from additional issues like obesity and allergic comorbidities, with the majority receiving specific treatment for their condition.
- * Key findings included high rates of pain, severe itching, and sleep disturbances, with patients reporting substantial reductions in work productivity and overall well-being.
Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial.
Allergy
October 2024
Department of Dermatology, Peking University People's Hospital, Beijing, China.
Background: Management of moderate-to-severe atopic dermatitis (AD) needs long-term therapy. Stapokibart is a humanized monoclonal antibody targeting interleukin-4 receptor α subunit (IL-4Rα), a shared receptor for IL-4 and IL-13 which are key pathogenic drivers of AD. In a pivotal phase 3 trial (NCT05265923), significant higher proportions of adult AD patients receiving stapokibart than placebo achieved ≥75% improvement from baseline in Eczema Area and Severity Index (EASI-75; 66.
View Article and Find Full Text PDFShort-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis).
J Dermatolog Treat
December 2024
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Article Synopsis
- * In a study with 85 adults, 49.4% of patients showed at least a 90% improvement in eczema severity, while 61.2% had a favorable assessment from doctors.
- * No major safety issues were reported, and naïve patients (those who hadn't previously tried treatment) had better outcomes than those who had failed another medication, highlighting its effectiveness in real-world settings.
Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study.
Clin Exp Dermatol
October 2024
Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Article Synopsis
- Upadacitinib, a JAK1 inhibitor, is effective for treating moderate-to-severe atopic dermatitis (AD), but its long-term retreatment effectiveness after discontinuation is not well-documented in real-world scenarios.
- A study of 62 Japanese patients evaluated the effectiveness and safety of retreatment, measuring outcomes like skin severity and itchiness before and after starting upadacitinib again.
- Results showed significant improvement in skin and itch scores at 12 weeks post-retreatment, with only mild side effects reported, indicating that upadacitinib is a viable option for managing AD over time.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!